Multidisciplinary Management of Pancreatic Cancer

Surgical Oncology Clinics of North America

Volumn 22, Issue 2, 2013, Pages 265-287

  Kumar, Rachit ^a   Herman, Joseph M ^a   Wolfgang, Christopher L ^a   Zheng, Lei ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Multidisciplinary care; Pancreatectomy; Pancreatic cancer; Radiation

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CANCER VACCINE; CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; STREPTOZOCIN;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BOLUS INJECTION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CHOLANGITIS; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; DUODENUM PERFORATION; DYSPEPSIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; JAUNDICE; LYMPHOCYTOPENIA; MALABSORPTION; MULTIDISCIPLINARY MANAGEMENT; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS FISTULA; PANCREAS METASTASIS; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PANCREATITIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRURITUS; REVIEW; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; STOMACH OBSTRUCTION; STOMACH PERFORATION; SURGICAL MORTALITY; TEAMWORK; THROMBOPHLEBITIS; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC;

EID: 84875516464     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2012.12.003     Document Type: Review

References (80)

1. Siegel R., Desantis C., Virgo K., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220.
2. Hayat M.J., Howlader N., Reichman M.E., et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12:20.
3. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893.
4. Abeloff M.D. Abeloff's clinical oncology 2008, Churchill Livingstone/Elsevier, Philadelphia. 4th edition.
5. Vincent A., Herman J., Schulick R., et al. Pancreatic cancer. Lancet 2011, 378:607.
6. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605.
7. Edge S.B. American Joint Committee on Cancer: AJCC cancer staging manual 2010, Springer, New York. 7th edition.
8. Tempero M.A., Arnoletti J.P., Behrman S.W., et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012, 10:703.
9. Callery M.P., Chang K.J., Fishman E.K., et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009, 16:1727.
10. Buchs N.C., Chilcott M., Poletti P.A., et al. Vascular invasion in pancreatic cancer: imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol 2010, 16:818.
11. Tseng J.F., Raut C.P., Lee J.E., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004, 8:935.
12. Leach S.D., Lee J.E., Charnsangavej C., et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998, 85:611.
13. Pelaez-Luna M., Takahashi N., Fletcher J.G., et al. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007, 102:2157.
14. Robbins S.L., Kumar V., Cotran R.S. Robbins and Cotran pathologic basis of disease 2010, Saunders/Elsevier, Philadelphia. 8th edition.
15. Crippa S., Partelli S., Boninsegna L., et al. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Ann Oncol 2012, 23:1928.
16. Winter J.M., Cameron J.L., Campbell K.A., et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006, 10:1199.
17. Griffin J.F., Smalley S.R., Jewell W., et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66:56.
18. Farma J.M., Santillan A.A., Melis M., et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008, 15:2465.
19. Wahl R.L., Herman J.M., Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol 2011, 21:88.
20. Berger A.C., Garcia M., Hoffman J.P., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008, 26:5918.
21. Pawlik T.M., Laheru D., Hruban R.H., et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 2008, 15:2081.
22. Desai S.P., Ben-Josef E., Normolle D.P., et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol 2007, 25:4587.
23. Varadhachary G.R., Wolff R.A., Crane C.H., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3487.
24. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496.
25. Heinrich S., Pestalozzi B.C., Schafer M., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:2526.
26. Le Scodan R., Mornex F., Partensky C., et al. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. Am J Clin Oncol 2008, 31:545.
27. Twombly R. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 2008, 100:1670.
28. O'Reilly E.M. Refinement of adjuvant therapy for pancreatic cancer. JAMA 2010, 304:1124.
29. Gillen S., Schuster T., Meyer Zum Buschenfelde C., et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
30. Katz M.H., Wang H., Balachandran A., et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 2012, 16:68.
31. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705.
32. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988, 80:751.
33. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985, 3:373.
34. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592.
35. Loehrer M., Langenbach C., Goellner K., et al. Characterization of nonhost resistance of Arabidopsis to the Asian soybean rust. Mol Plant Microbe Interact 2008, 21:1421.
36. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326.
37. Krishnan S., Rana V., Janjan N.A., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47.
38. Schneider B.J., Ben-Josef E., McGinn C.J., et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:1325.
39. Mishra G., Butler J., Ho C., et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 2005, 28:345.
40. Ko A.H., Quivey J.M., Venook A.P., et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:809.
41. Moureau-Zabotto L., Phelip J.M., Afchain P., et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 2008, 26:1080.
42. Schellenberg D., Goodman K.A., Lee F., et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678.
43. Martin R.C., McFarland K., Ellis S., et al. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 2012, 215(3):361-369.
44. Cunningham D., Chau I., Stocken D.D., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513.
45. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817.
46. Wolfgang C.L., Corl F., Johnson P.T., et al. Pancreatic surgery for the radiologist, 2011: an illustrated review of classic and newer surgical techniques for pancreatic tumor resection. AJR Am J Roentgenol 2011, 197:1343.
47. Neoptolemos J.P., Stocken D.D., Dunn J.A., et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001, 234:758.
48. Richter A., Niedergethmann M., Sturm J.W., et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003, 27:324.
49. Wagner M., Redaelli C., Lietz M., et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004, 91:586.
50. Tomlinson J.S., Jain S., Bentrem D.J., et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 2007, 142:767.
51. Asiyanbola B., Gleisner A., Herman J.M., et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 2009, 13:752.
52. Berger A.C., Watson J.C., Ross E.A., et al. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004, 70:235.
53. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997, 226:248.
54. Nathan H., Cameron J.L., Goodwin C.R., et al. Risk factors for pancreatic leak after distal pancreatectomy. Ann Surg 2009, 250:277.
55. Gunderson L.L., Tepper J.E., Bogart J.A. Clinical radiation oncology 2012, Elsevier Saunders, Philadelphia. 3rd edition.
56. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019.
57. Koong A.C., Le Q.T., Ho A., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58:1017.
58. Koong A.C., Christofferson E., Le Q.T., et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320.
59. Chang D.T., Schellenberg D., Shen J., et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009, 115:665.
60. Mahadevan A., Jain S., Goldstein M., et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78:735.
61. Polistina F., Costantin G., Casamassima F., et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17:2092.
62. Herman JM, Chang DT, Goodman KM, et al. A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma. Poster presentation at the 2012 ASCO Annual Meeting. Chicago, June 1-5, 2012.
63. Neoptolemos J.P., Moore M.J., Cox T.F., et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012, 308:147.
64. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899.
65. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200.
66. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267.
67. Bakkevold K.E., Kambestad B. Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater-the prognostic factors influencing the long-term results. A prospective multicentre study. Eur J Surg Oncol 1993, 19:147.
68. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776.
69. Neoptolemos J.P., Stocken D.D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073.
70. Lutz E., Yeo C.J., Lillemoe K.D., et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011, 253:328.
71. Picozzi V.J., Abrams R.A., Decker P.A., et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011, 22:348.
72. Palmer D.H., Stocken D.D., Hewitt H., et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007, 14:2088.
73. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509.
74. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24:3946.
75. Poplin E., Feng Y., Berlin J., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778.
76. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960.
77. Von Hoff D.D., Ramanathan R.K., Borad M.J., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548.
78. Fine R.L., Fogelman D.R., Schreibman S.M., et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008, 61:167.
79. De Jesus-Acosta A., Oliver G.R., Blackford A., et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012, 69:415.
80. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10:1311.